• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Aging . Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19

tetano

Editor, Senior Moderator
Nat Aging


. 2024 Jun 25.
doi: 10.1038/s43587-024-00644-w. Online ahead of print. Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19

Beatrice Dallan[SUP] #[/SUP][SUP] 1 [/SUP], Davide Proietto[SUP] #[/SUP][SUP] 1 [/SUP], Martina De Laurentis[SUP] 1 [/SUP], Eleonora Gallerani[SUP] 1 [/SUP], Mara Martino[SUP] 1 [/SUP], Sara Ghisellini[SUP] 2 [/SUP], Amedeo Zurlo[SUP] 3 [/SUP], Stefano Volpato[SUP] 3 [/SUP], Benedetta Govoni[SUP] 3 [/SUP], Michela Borghesi[SUP] 4 [/SUP], Valentina Albanese[SUP] 5 [/SUP], Victor Appay[SUP] 6 [/SUP], Stefano Bonnini[SUP] 4 [/SUP], Sian Llewellyn-Lacey[SUP] 7 [/SUP], Salvatore Pacifico[SUP] 1 [/SUP], Laura Grumiro[SUP] 8 [/SUP], Martina Brandolini[SUP] 8 [/SUP], Simona Semprini[SUP] 9 [/SUP], Vittorio Sambri[SUP] 8 9 [/SUP], Kristin Ladell[SUP] 7 [/SUP], Helen M Parry[SUP] 10 [/SUP], Paul A H Moss[SUP] 10 [/SUP], David A Price[SUP] 7 11 [/SUP]; RIV Study Group; Antonella Caputo[SUP] 1 [/SUP], Riccardo Gavioli[SUP] 1 [/SUP], Francesco Nicoli[SUP] 12 [/SUP]



Collaborators, Affiliations
Abstract

Adenoviral and mRNA vaccines encoding the viral spike (S) protein have been deployed globally to contain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Older individuals are particularly vulnerable to severe infection, probably reflecting age-related changes in the immune system, which can also compromise vaccine efficacy. It is nonetheless unclear to what extent different vaccine platforms are impacted by immunosenescence. Here, we evaluated S protein-specific immune responses elicited by vaccination with two doses of BNT162b2 or ChAdOx1-S and subsequently boosted with a single dose of BNT162b2 or mRNA-1273, comparing age-stratified participants with no evidence of previous infection with SARS-CoV-2. We found that aging profoundly compromised S protein-specific IgG titers and further limited S protein-specific CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cell immunity as a probable function of progressive erosion of the naive lymphocyte pool in individuals vaccinated initially with BNT162b2. Our results demonstrate that primary vaccination with ChAdOx1-S and subsequent boosting with BNT162b2 or mRNA-1273 promotes sustained immunological memory in older adults and potentially confers optimal protection against coronavirus disease 2019.


 
Back
Top Bottom